Aktuellt
SENASTE
For Q2, we expect a continued recovery of Bactiguard’s underlying business along with increased costs y/y and for the company to deliver on its growth strategy. Over the next couple of years, we expect Bactiguard to expand its underlying business (e.g. deeper penetration of its catheter portfolio and broader wound-care sales) and start to deliver on already secured licence partnerships as well as expanding into further collaborations.
LÄS MER
